The Ministry of Health withdrew QazVac from WHO registration after spending billions of tenge

Kazakhstan no longer plans to seek international recognition for its QazVac coronavirus vaccine.

The Ministry of Health withdrew QazVac from WHO registration after spending billions of tenge

Health Minister Akmaral Alnazarova said that continuing the registration is no longer advisable. More than 2 billion tenge was spent on developing the vaccine, and about 7 billion on the plant, according to Informburo.

The gist in brief

  • The Health Minister said on November 3, 2026 that QazVac is not registered with the World Health Organization (WHO) "due to lack of advisability."
  • More than 2 billion tenge was allocated to developing the vaccine, and about 7 billion tenge to the plant in Zhambyl Region.
  • The WHO imposed additional requirements in 2023-2024; now, according to the minister, the issue has lost its relevance.
  • Instead, the Health Ministry is preparing a project for a new laboratory complex to test all vaccines; the design documentation is planned to be completed in April 2027.

What the minister said

Alnazarova answered journalists' questions after a government meeting. According to her, the QazVac vaccine is not registered with the WHO due to lack of advisability. She added that in 2023-2024 the WHO imposed additional requirements for registration, but now the issue has lost its relevance. The minister did not specify what exactly those requirements were.

How much was spent on the vaccine and the plant

More than 2 billion tenge was allocated to developing QazVac, and production in Zhambyl Region cost about 7 billion tenge. The statement contains no information on how many doses were produced and used, nor any data on what the plant is currently doing.

Why the vaccine did not pass the WHO procedure

Back in January 2024, Deputy Health Minister Aizhan Yesmagambetova explained that the WHO requires a full production cycle: from obtaining the biomass to filling and packaging. According to her, the plant for QazVac was built from scratch; at that time the filling line had a GMP (good manufacturing practice) certificate, while the biomass production complex was still under construction. This was reported by Kursiv. At the same time, the Health Ministry cited the vaccine's efficacy in clinical trials: 100% in the first phase, 96% in the second, and 84% in the third.

What the Health Ministry plans instead of registration

In April 2026, Kazakhstan reached the third level of maturity of its national medicines regulatory system under the WHO classification. For the fourth level, according to WHO experts, a new laboratory complex is needed where all vaccines produced in the country and imported into it will be tested. The prime minister gave the instruction, a plot of land has been allocated, the design documentation is planned to be completed in April 2027, and construction will begin after that.

Author's conclusion

To register with the WHO, the Health Ministry would have had to complete the full production cycle at the plant, but it chose a different path: investing in a laboratory complex needed for the fourth level of maturity of the regulatory system. In essence, the priority has shifted from promoting its own vaccine to quality control of all vaccines in the country. How many doses the plant produced and what it is currently doing has not yet been disclosed.